Compare TURB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | LGVN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 25.9M |
| IPO Year | 2023 | 2021 |
| Metric | TURB | LGVN |
|---|---|---|
| Price | $1.15 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 269.5K | ★ 444.4K |
| Earning Date | 04-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.48 |
| 52 Week High | $20.44 | $1.23 |
| Indicator | TURB | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 31.28 | 62.15 |
| Support Level | $1.13 | $0.62 |
| Resistance Level | $1.22 | $0.87 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.49 | 73.23 |
Turbo Energy SA is an integrator of AI-driven energy storage and intelligent energy management solutions focused on transforming how energy is generated, stored, optimized, and consumed across residential, commercial, industrial, and utility-scale applications. It operates at the intersection of renewable energy infrastructure, energy storage, and software-driven optimization, combining battery systems, solar integration, and proprietary Artificial Intelligence (AI) technologies into unified intelligent energy platforms. Its solutions are designed to help customers reduce energy costs, improve operational resilience, increase energy independence, and optimize energy performance in increasingly decentralized and volatile energy markets. It generates the majority of its revenue from Spain.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.